Overview

The Division of Pediatric Endocrinology and Metabolism offers 2 Fellowship training programs to residents successfully completing the two-year residency training in Pediatric Endocrinology; one is of 1 y duration and the other is 2 years. This 2-year program is essentially tailored for trainees to complete a graduate degree in Epidemiology, Education, or Public Health or Ethics. Alternatively, this additional time is generally used to complete basic science or clinical research projects, under staff supervision. Generally, research activities will be linked to a formal academic program such as a PhD or Masters.

Trainees will spend more than 90% of their time involved in these activities; one clinic per week may be arranged to provide clinical contact, usually only in the first year. This limited contact will not dilute the clinical exposure of any of the more junior house staff. The fellows will not be involved in any on-call activities. All clinical activities will be arranged according to the trainee’s interest, as these are not considered a mandatory component of the Fellowship.

Dependent on fellow interest, opportunity exists to participate in a number of didactic educational activities including tutoring first year medical students in endocrine physiology tutorials or teaching of junior house staff. The trainee is invited to participate in all Department of Pediatrics academic activities including those within the Division. See below for a schedule of the usual activities.

Prior to the onset of the fellowship, the fellow and program director will together predetermine an individualized set of training goals. Goals of the fellowship and trainee performance will be reviewed quarterly. The trainee will have reciprocal opportunities to assess their supervisors and the training program.

General information

The duration of this training will be a minimum of 18 months but typically 24 months.

Trainees will only be eligible for this training if they are deemed eligible if they have or will soon receive Royal College or American Board certification in Endocrinology; this assures that they would be eligible to receive a training card from the College des Medecins du Quebec.

The Pediatric Endocrinology Program Director and the Training Committee will supervise the Fellowship program. They will be responsible for implementation, recruitment and supervision of
the Fellowship, and will ensure that the Endocrine or Pediatric residents or medical students will continue to experience adequate clinical exposure, supervision and educational content.

**Graduate school programs (usually reserved for the 2-year fellowship stream)**
The Fellow will need to apply well in advance to the start of the Fellowship to ensure that they will be accepted. These details can be discussed in depth with the Program Director. The most frequent request by the potential Fellows is to apply and complete a Masters in Epidemiology at McGill. This can usually be completed in about 24-30 months; in the first year, all of the course material can be completed. The next year allows the completion of a thesis project, with an expectation to present and publish the findings. If the Fellow was an endocrine resident at McGill, the course work is often completed in the second year and the thesis is undertaken in the Fellowship.

Trainees may also apply to other graduate degrees at the university including Education. Alternatively, they may consider completing degrees by distance education in three main disciplines; Epidemiology, Medical Education or Public Health offered by such institutions as the London School of Hygiene and Tropical Medicine, Johns Hopkins or Aberdeen.

**Optional clinical activities**
Generally the trainees are interested in attending a general endocrinology clinic on Monday or Tuesday afternoons (1300-1700). The staff consists of 2 physicians on Mondays (1 on Tuesday) and usually one endocrine resident, with perhaps a medical student and 1 or 2 residents. There are over 25 patients seen by the house staff on Mondays, less on Tuesdays. If the Fellow wishes to attend this clinic, then patients, who need to be seen more urgently and have been triaged to attend an ‘office’ visit by only the staff, could be seen by the Fellow. The staff, who would have evaluated the patient by themselves, can attend the clinic to review the case. If this staff is already booked in the clinic, then they will arrange their time to attend the clinic earlier than usual to review the Fellow’s case/s. We have experience with this and have found that the house staff attending the usually scheduled clinic is given the usual amount of attention, while allowing the Fellow to see patients.

If the program director deems that the clinic has been assigned very few house staff, the Fellow can attend and work in parallel with the usual house staff.
Weekly schedule

Monday afternoon- General endocrine clinic 1300- 1700 (if interested)*
Tuesday morning Diabetes clinic 0800- 1200 (if interested)*
Wednesday afternoon 1330- 1630 Diabetes/Endocrinology rounds, journal club or research presentation in the academic year
Thursday morning (twice per month) Lipid clinic 0900-1200*
Thursday afternoon 1330-1530 Endocrine resident teaching (if interested)
Friday afternoon- house staff teaching (Fellow may be the facilitator, if interested)
* the Fellow will select one of these clinics per week
### Division of Endocrinology and Metabolism Statistics:

#### STATISTICS IN PEDIATRIC ENDOCRINOLOGY

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENDOCRINOLOGY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW PATIENTS/CONSULTS</td>
<td>550</td>
<td>237</td>
<td>468</td>
<td>452</td>
<td>414</td>
<td>345</td>
</tr>
<tr>
<td>FOLLOW-UP</td>
<td>1413</td>
<td>1632</td>
<td>1340</td>
<td>1266</td>
<td>1144</td>
<td>1017</td>
</tr>
<tr>
<td>ADMISSIONS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ENDO OFFICE (2005-2006-)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOLLOW-UP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMERGENCY: NEW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WARDS: NEW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOLLOW-UPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPID CLINICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW PATIENTS/CONSULTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOLLOW-UPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BONE CLINICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW PATIENTS/CONSULTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOLLOW-UPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BONE OFFICE OFFICE CONSULTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>HEALTHY WEIGHT CLINICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW PATIENTS/CONSULTS</td>
<td>60</td>
<td>51</td>
<td>42</td>
<td>32</td>
<td>20</td>
<td>9</td>
</tr>
<tr>
<td>FOLLOW-UPS</td>
<td>137</td>
<td>107</td>
<td>80</td>
<td>86</td>
<td>106</td>
<td>103</td>
</tr>
<tr>
<td>WEIGHT MANAGEMENT OFFICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSULTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOLLOW-UPS</td>
<td>35</td>
<td>23</td>
<td>58</td>
<td>43</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>CIU:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW PATIENTS/CONSULTS</td>
<td>50</td>
<td>45</td>
<td>34</td>
<td>45</td>
<td>48</td>
<td>43</td>
</tr>
<tr>
<td>FOLLOW-UPS</td>
<td>393</td>
<td>426</td>
<td>381</td>
<td>362</td>
<td>338</td>
<td>262</td>
</tr>
<tr>
<td>TOTALS</td>
<td>4331</td>
<td>3953</td>
<td>3947</td>
<td>3,841</td>
<td>3,528</td>
<td>2,866</td>
</tr>
<tr>
<td>METABOLISM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW PATIENTS/CONSULTS</td>
<td>98</td>
<td>96</td>
<td>65</td>
<td>64</td>
<td>77</td>
<td>95</td>
</tr>
<tr>
<td>FOLLOW-UPS</td>
<td>1810</td>
<td>1807</td>
<td>1078</td>
<td>1968</td>
<td>2,093</td>
<td>1,965</td>
</tr>
<tr>
<td>ADMISSIONS</td>
<td>87</td>
<td>73</td>
<td>71</td>
<td>71</td>
<td>65</td>
<td>52</td>
</tr>
<tr>
<td>SUBTOTALS</td>
<td>1995</td>
<td>1976</td>
<td>2114</td>
<td>2,103</td>
<td>2,235</td>
<td>2,017</td>
</tr>
<tr>
<td>GRAND TOTALS</td>
<td>6326</td>
<td>5929</td>
<td>6061</td>
<td>5,944</td>
<td>5,763</td>
<td>4,883</td>
</tr>
</tbody>
</table>
Additional pedagogic activities

All trainees are encouraged to attend at least one conference per year; this is often the Endocrine Society, American Diabetes Association or the Canadian Diabetes meeting/Endocrinology meeting. Our division has adequate funding to assist with registration costs and some travel costs for endocrine residents and Fellows. The Fellows are also able to be granted additional funds from the MCH research institute, if their abstracts have been accepted for presentation.

Research Activities:

**Cynthia Gates Goodyer Ph.D.**

My laboratory has been studying various aspects of early growth and development in the human. Our target community has been those fetuses and infants who do not grow well despite the absence of chronic disease. Most recently, we have focused on molecular aspects of the hGH receptor (hGHR) and their clinical implications. We are:

1) mapping the 5' flanking region of the *hGHR* gene and analysing the promoter regulatory mechanisms;

2) examining the 3' untranslated region (UTR) of the *hGHR* gene for miRNA regulatory elements;

3) examining the promoter and 3'UTR regions of the *hGHR* gene for polymorphisms/mutations in individuals exhibiting abnormal growth (idiopathic short stature, cancer);

4) studying the mechanisms regulating hGHR isoform expression in human adipocytes and chondrocytes and the role of the hGH/hGHR axis in these cells during development and with patho-physiological states (obesity, short stature, cancer).

**Aimee K. Ryan, Ph.D.**

My lab is interested in understanding how organs are formed and patterned during embryonic development. The pituitary gland originates from an invagination of oral ectoderm (Rathke’s pouch) and the evagination of the infundibulum from the ventral diencephalon (site of the future hypothalamus) within the first 5 weeks of embryogenesis. Subsequently differentiated cell types appear in response to signalling molecules released from the surrounding tissues and intracellular interactions. In addition, we are studying the function of the homeodomain transcription factor, Pitx2. Mutations in the Pitx2 homeodomain and transactivation domain lead to Rieger’s syndrome, an autosomal dominant disorder which often has associated growth defects.

**C. Rodd M.D.**

1. Dose finding study of vitamin D3 in breastfed infants in Montreal. I am the PI with Dr H. Weiler, Macdonald campus, evaluating the optimal vitamin D dose for infants with longitudinal follow up of
children till the age of 3 years. Novel outcomes such as muscle strength as well as bone density and clinical biochemistry are being examined in over 130 infants.

2. Socioeconomic determinants of health utilization is a recent research interest. I have completed a project assessing diabetes mellitus control in the children followed at the Montreal Children’s Hospital as well as admission and use of diabetes educator resources. This has led to further applications submitted to CIHR to assess uptake of vitamin D usage in the province and its determinants.

3. STOPP Steroid-induced Osteoporosis in the Pediatric Populations – Canadian Incidence Study (STOPP-CIS). I am a Co-PI in a multicentre CIHR funded, longitudinal study looking at the impact of glucocorticoids on bone health in children with leukemia, rheumatologic disorders and nephrotic syndrome. Significant findings are elevated prevalence and incidence of vertebral fractures particularly in children treated for leukemia. Dr. Leanne Ward, CHEO is the PI for this project.


R. Barnes, M.D.
Pediatric type 1 diabetes is believed to be increasing in incidence, particularly in younger children. The province of Quebec does not have a surveillance mechanism to monitor incidence and prevalence of any type of pediatric diabetes. Our multicentre group is performing a local feasibility study with a view to later establishment of a Quebec-wide registry of pediatric diabetes. Supported by a grant from Diabête Québec.

Recent basal insulin analogues were introduced to "perfect" basal-bolus insulin replacement therapy in type 1 diabetes, but the lunchtime dose is problematic in younger school-aged children. Taking the next step from our outcomes audit for children who retain a dose of intermediate insulin at breakfast in lieu of any lunchtime insulin dose, we seek to explore the frequency of
hypoglycemic events in those children taking robust evening basal doses (and smaller intermediate morning doses) vs. those taking light evening basal doses (and stronger morning intermediate doses). Co-Investigator: Nancy Dumouchel. Trainee: Dr. Asma Binjab.

Short-term metabolic control results of insulin pump therapy for children with type 1 diabetes are encouraging, but long-term data are sparse and conflicting. Taking the next step from our outcomes audit of children followed on an insulin pump for up to eight years in our clinic, we seek to compare outcomes in a cohort of age-, sex- and diabetes duration-matched children on insulin injections, to understand whether the overall positive long-term experience in pump users can be ascribed to the effect of the pump, or whether children on injections also enjoyed a comparable positive secular trend. Co-Investigator: Evelyne Pytka. Trainee: Eiman Al-Sideeqi.

P. Krishnamoorthy, M.D.

Familial hypercholesterolemia is often detected in childhood. Unfortunately, the treatment options that are available are few, and side effects of these treatments are common. I am the Principal Investigator of the MCH site of a multicenter, international trial looking at the safety and efficacy of a new treatment (ezetimibe) for familial hypercholesterolemia in children aged 6-10 years.

As Medical Director of Camp Carowanis, a summer camp for children living with diabetes, I am interested in conducting research in the camp setting. We are currently examining blood glucose trends with camp-related activity and the incidence of hypoglycaemia following transition from home to camp.

Finally, as the Director of Pediatric Undergraduate Education at McGill, I am enthusiastic to pursue research in medical education. One of my current interests is the use of a double-circuit observed standardized clinical examination for pediatric residents, in order to explore the utility of direct observation as a means of learning.

(ii) Endocrine Genetics Laboratory

C. Polychronakos M.D.

In the past 5 years my efforts have centered on elucidating the molecular genetics of diabetes.


- A genome-wide association study for type 2 diabetes: Facing the alarming increase of type 2 diabetes among children, I joined the Diabetes Gene Discovery Group, a collaboration between McGill, Université de Montréal and Centre National de Recherche Scientifique in Lille, France aimed at elucidating the genetics of type 2 diabetes by a GWA study in a French cohort, funded by Genome Canada and Génome Québec. Four loci were discovered in Stage 1
(Nature 445(7130):881-5), one of the first major proofs-of-principle for the GWA approach. I am corresponding author in this paper, which had an accompanying News and Views write-up and was widely covered in the world media.

- **The insulin gene in type 1 diabetes (T1D).** Following up on a previous observation that a polymorphism upstream of the insulin gene confers diabetes risk by modulating expression levels in the thymus which, we hypothesized, modulates insulin-specific T-cell tolerance (Nature Genetics 15: 289-292, 1997, front page of the Montreal Gazette) I proceeded to test predictions of this model with functional studies in humans (Diabetes, 2005, S18-24, Proc Natl Acad Sci, 2006, 103:11683-8 and Diabetes 2007 56:709-13) and a mouse KO with thymus-specific deficiency (Diabetes 51:1383-1390, 2002). We also pinpointed the rare cells in the thymus that make insulin (Diabetes, 53:354-9, 2004) and show that insulin transcription in these cells depends on immune rather than metabolic stimuli (Diabetes 55:2595-601, 2006).

(iii) **Diabetes Research**

L. Legault, M.D.

- TRIGR study-prevention of type 1 diabetes in high risk neonates through a nutritional intervention. This is a 10 year study which should be finished in 2016. Forty three children are followed at the MCH and have yearly assessment. The nutritional intervention is over for them and we are in the observation period for diabetes status.

- Impact of treatment of obstructive apnea on the markers of the metabolic syndrome in teenagers. Diagnosed OSA patients will have assessment of their insulin resistance and type 2 diabetes status before and after OSA treatment.

- Qualitative study on the reasons to undertake a weight loss program. Families that choose (or not) to continue being followed in the healthy weight clinic will be interviewed to determine what are the driving forces that lead a family to decide to undertake a weight reduction program.

- Use of a double hormone (insulin and Glucagon) in an insulin pump to counteract the effects of hypoglycemia. Glucagon will be added to a conventional insulin pump to prevent hypoglycemia as "proof or principle" intervention to prevent hypoglycemia. This strategy will be tested overnight and after exercise, two situations commonly associated with hypoglycemia.

- Impact of hypoglycemia on memory. Type 1 diabetics known for previous severe hypoglycemic episodes will be compared with non diabetics on a computer based memory test to unravel the impact of hypoglycemia on memory patterns.

- Establishing a type 1 diabetes registry using the government administrative databases.

H. Bui, M.D.

Diabetic ketoacidosis (DKA) at presentation of type 1 diabetes is a preventable complication that affects 15 to 67% of children. I am interested in studying the factors that predispose to DKA at diagnosis, the prevalence of medical encounters prior to diagnosis, and the possible means to prevent this potentially fatal complication.
Poor metabolic control in type 1 diabetes, as evidenced by a high hemoglobin A1c (HbA1c), increases the risk of long-term microvascular complications. I am interested in studying potential adjuvant therapies with an aim to decrease HbA1c in poorly controlled adolescents, including insulin sensitizers and novel reminder techniques. Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of ovarian dysfunction affecting up to 10% of reproductive age women. Non-alcoholic fatty liver disease (NAFLD) is a common complication of pediatric obesity, with steatosis occurring in 50-80% of obese children. The association of PCOS and NAFLD has only been evaluated in a few recent studies of adult women. Compared to their non-PCOS counterparts of similar BMI, women with PCOS have greater prevalence of insulin resistance, hepatic steatosis, and elevated ALT. This suggests that insulin resistance is a common feature of both PCOS and NAFLD, and that PCOS, independent of BMI, is a risk factor for NAFLD. With the rising incidence of childhood obesity, NAFLD and PCOS may become more prevalent health problems in adolescents. I am investigating the burden of NAFLD in adolescents with PCOS.

John Mitchell, M.D.

1) Rare forms of monogenic diabetes are a focus. We have gathered data on a number of families and are looking for candidate genes. We identified a new locus in two sibs with neonatal diabetes and intestinal malformations (Nature 463(7282):775-80, 2010).

2) I spend 50% of my time in biochemical genetics. I am involved in the following research studies
   a. Characterization of bone health in MPS IV A patients (PI)
   b. Multicenter clinical study looking at phenotype of Morquio Syndrome (PI)
   c. Multicenter Phase II trial evaluating effectiveness of enzyme replacement therapy in the treatment of MPS IVA
   d. Principle investigator of multinational study investigating effectiveness of Tetrahydrobiopterin in treating ADHD symptoms in PKU patients
   e. Principle investigator of multinational study evaluating effectiveness of Tetrahydrobiopterin as an alternative therapy for phenylketonuria in 0-6 year olds PKU patients
   f. Co-investigator for study evaluating incidence of Tay-Sachs disease in the French Canadian population of Quebec

Meranda Nakhla, M.D.

Health services research with focus on diabetes mellitus in children and youth
   • Epidemiology and trends of diabetes mellitus among children and youth in Quebec
   • Epidemiology of health services use by children and youth with Diabetes Mellitus in Quebec
   • Evaluation of health services provided to youth with diabetes in Quebec

Research
The Fellow will select at least one project and usually work with one of these supervisors. We are lucky enough to have 2 other endocrine basic scientists (Drs Goodyer and Ryan), at the MCH-RI,
who have also supervised Fellows. The Fellow might additionally contemplate a joint research project between the pediatric and adult endocrine sites at McGill.

At the end of the fellowship, the trainee will present to the Program Director with an updated copy of their CV, which will highlight their achievements over this time period.

**Administrative responsibilities**

Fellows will be responsible for the coordination of their clinical activities. They may decide to attend the regularly scheduled clinics or wish to arrange to see more urgent referrals that would be seen exclusively by a staff member earlier than 6m waiting period it would otherwise take. Additionally, they will be involved in the teaching schedule for house staff and may help to select topics and then supervise the Friday afternoon sessions.

**Evaluation**

The Program Director will meet with the Fellow at least quarterly; the progress with the course work, research project and possible clinical exposure will be explored. Evaluation forms will be reviewed at this time. If issues arise prior to these meetings, the Fellow may approach the Program Directors, the Training Committee members or any member of the staff to discuss issues. At the end of the Fellowship, a final written evaluation will be completed and placed in the Fellow’s file. The Fellow will have the opportunity to provide feedback to the Training Committee and Fellowship Program Director anonymously. The Training Committee will assess the quality of the curriculum of the Fellowship, at least on an annual basis.

The Fellow will received a signed certificate outlining the duration of their training at McGill University.

If the trainee is involved in clinical outpatient care, the specific objectives and evaluation form for this type of exposure will also be completed on a quarterly basis.

**General competencies**

**Medical Expert**-

1. To apply relevant clinical or basic science information to research development
2. To demonstrate medical expertise in situations other than direct patient care
3. To provide advice and education to other health care providers with respect to patient care, and legal opinions.

**Communicator**
1. To document research ideas as a protocol, manuscript or lecture
2. To develop good communication skills with research subjects, supervisor, trainees and/or team members.

**Collaborator**
1. To contribute effectively to other interdisciplinary team activities, particularly those most often associated with endocrinology
2. To acquire the skill of identifying potential collaborators locally, nationally or internationally and the skill of proposing a mutually beneficial academic collaboration

**Manager**
1. To appropriately allocate time to research education, and other professional commitments
2. To utilize resources effectively when designing and implementing a research project
3. To manage a research operating budget

**Health advocate**
1. To identify determinants of health that affect a patient
2. To use research as a tool to advocate for health changes and to disseminate health information

**Scholar**
1. To formulate a clinical/research question and research protocol.
2. To complete a project based on this question
3. To contribute to the development of new knowledge
4. To critically appraise medical literature
5. To undertake and complete advanced course work (in epidemiology, public or community health, or educational programs).

**Professional**
1. To exhibit appropriate personal and interpersonal professional behaviour
2. To demonstrate responsibility and self-discipline
3. To recognize one’s own limitations
4. To demonstrate a willingness to accept peer and supervisor reviews of professional competence.
5. To demonstrate an understanding of the principles of medical ethics as they relate to clinical research including autonomy, beneficence/ nonmalificennce, justice and confidentiality

If the trainee is involved in clinical outpatient care, the specific objectives and evaluation form for this type of exposure will also be completed on a quarterly basis.
<table>
<thead>
<tr>
<th>MEDICAL EXPERT</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td>To apply clinical or basic science information to research development</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To demonstrate medical expertise in situations other than direct patient care</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To respond and advise requests from other health care providers with respect to patient care, education of provider and legal opinions</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMMUNICATOR</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td>To document research ideas as a protocol, manuscript or lecture</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To develop good communication skills with research subjects, supervisor, trainees or team members</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COLLABORATOR</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td>To contribute effectively to other interdisciplinary team activities, particularly those most often associated with endocrinology</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To interact with and contribute knowledge to the field of endocrinology, both with respect to patient care and in collaboration with other disciplines</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MANAGER</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td>To allocate time appropriately to address research priorities with educational priorities and other professional commitments</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To utilize resources effectively when designing and implementing research projects</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To manage a research operating budget</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HEALTH ADVOCATE</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td>To identify means of health that affect health in patients</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To use research as a tool to advocate for health changes</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCHOLAR</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td>To formulate a clinical research question and research protocol</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To complete a project based on this question</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To contribute to the development of new knowledge</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To critically appraise medical literature</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PROFESSIONAL</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td>To exhibit appropriate personal and interpersonal professional behaviours</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To demonstrate responsibility and self-discipline</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To recognize one's own limitations</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To demonstrate willingness to accept peer and supervisor reviews of professional competence</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>To demonstrate an understanding of the principles of medical ethics as they relate to clinical research including autonomy, beneficence/non-maleficence, confidentiality</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GLOBAL EVALUATION OF COMPETENCE AND PROGRESS</th>
<th>Could Not Judge</th>
<th>Unsatisfactory</th>
<th>Borderline</th>
<th>Satisfactory</th>
<th>Supreme</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMMENTS (Including Strengths, Weaknesses and Need for Special Attention. Please use reverse side if necessary)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signature of Supervisor</th>
<th>Date</th>
<th>Signature of Trainee</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DISAGREE □ AGREE □

APPLICATION FORM FOR FELLOWSHIPS

Name of institution: McGill University

Location: Montreal

Type of Fellowship: Clinical research or basic research- in conjunction with graduate school degree

- Program Information:
  - Number of fellowship positions requested: 2
  - Academic affiliation: McGill University
  - Name of hospitals involved in training: Montreal Children’s Hospital
    - % time spent by the fellow in each institution: 100%

- Background:

  The Division of Pediatric Endocrinology and Metabolism offers a Fellowship training program to residents successfully completing the two-year residency training in Pediatric Endocrinology. This additional training aims to provide structured individually tailored academic training; most trainees will use this time to complete a graduate degree in Epidemiology, Education, or Public Health or Ethics. Alternatively, this additional time is generally used to complete basic science or clinical research projects, under staff supervision. Generally, research activities will be linked to a formal academic program such as a PhD or Masters.

  Trainees will spend more than 90% of their time involved in these activities; one clinic per week may be arranged to provide clinical contact. This limited contact will not dilute the clinical exposure of any of the more junior house staff. The fellows will not be involved in any on-call activities. All clinical activities will be arranged according to the trainee’s interest, as these are not considered a mandatory component of the Fellowship.

  Dependent on fellow interest, opportunity exists to participate in a number of didactic educational activities including tutoring first year medical students in endocrine physiology tutorials or teaching of junior house staff. The trainee is invited to participate in all Department of Pediatrics academic activities including those within the Division. See below for a schedule of the usual activities.

  Prior to the onset of the fellowship, the fellow and program director will together predetermine an individualized set of training goals. Goals of the fellowship and trainee performance will be reviewed quarterly. The trainee will have reciprocal opportunities to assess their supervisors and the training program.
Research activity- see above

Publications from all physicians:-

CONSTANTIN POLYCHRONAKOS, M.D.


27. H-Q Qu, JP Bradfield, SFA Grant, H Hakonarson, C Polychronakos and the Type 1 Diabetes Genetics Consortium. Association of RASGRP1 with type 1 diabetes is revealed by combined follow-up of two genome-wide studies. *J Med Genet* 2009;46;553-554. PMID: 19465406

28. Hui-Qi Qu, Karine Jacob, Sarah Fatet, Bing, Ge, David Barnett, Olivier Delattre, Damien Faury, Alexandre Montpetit, Lauren Solomon, Peter Hauser, Miklos Garami, Laszlo Bognar, Zoltan Hansely, Robert Mio, Jean-Pierre Farmer, Steffen


40. Qu HQ, Bradfield JP, Li Q, Kim C, Frackleton E, Grant SFA, Hakonarson H, Polychronakos C. In Silico Replication of the Genome-wide Association Results of the Type 1 Diabetes Genetics Consortium. Human Molecular Genetics 2010 Apr 8. PMID: 20378605


CELIA RODD, M.D.


PUBLICATIONS:
Trainees **


12. Jacqueline Halton; Isabelle Gaboury; Ronald Grant; Nathalie Alos; Elizabeth Cummings; Maryann Matzinger; Nazih Shenouda; Brian Lentle; Sharon Abish; Stephanie Atkinson; Elizabeth Cairney; David Dix; Sara Israels; David Stephure; Beverly Wilson; John Hay; David Moher; Frank Rauch; Kerry Siminoski; Leanne Marie Ward and STOPP Consortium. Advanced Vertebral Fracture among Newly Diagnosed Children with Acute Lymphoblastic Leukemia: Results of the Canadian STeroid-associated Osteoporosis in the Pediatric Population (STOPP) Research Program (Consortium member) Published JBMR 2009


JOHN MITCHELL, M.D.


PREETHA KRISHNAMOORTHY, M.D.


LAURENT LEGAULT, M.D.


6. EF Gregory, DL Crouse, P Krishnamoorthy and L. Legault, Type 1 vs. Type 2 Diabetes: Socioeconomic Differences in a Pediatric Population in Montreal., *Can J of Diabetes*, Dec 2010


9. Legault L and VanVliet G, Persistent hypothyroidism following hemithyroidectomy for autonomous hot nodules, in preparation


11. Beaucage P, Gold M, Grover S and Legault L, Metabolic profiles and fitness levels one year after attending an intensive summer program, the cardiovascular health improvement program for teens: (CHIP4teen) program, in preparation

HELEN BUI, M.D.


*Bui H*, Daneman D. “Type 1 Diabetes in Childhood.” *Medicine UK* 2006 Mar;34(3):113-7


Meranda Nakhla, M.D.


- **Mission-**

To train pediatric endocrinology residents to become academicians, which usually entails combined research training and graduate degrees in either Epidemiology, Public Health or Education.

- **Outline how intended fellowship will enhance residency training**

The Fellows will act as role models and provide some mentorship for the residents. They will likely be able to provide some insight into the rationale for extra training, the process of application for an academic position. On a daily basis, they may provide some academic and clinical insights.

**Name of the Fellowship Program Director:** Dr Celia Rodd

**Names of the Teaching Faculty:** this includes the entire faculty

- **Roles**

Our division has a large number of staff involved in many academic endeavours including patient care, research and education. We see a wide range of pathologies and run several specialized clinics. The staff have a broad base of knowledge, as well, most have focused areas of clinical and basic research and patient care.

- **Summary of clinical practice-please see above for clinic details**

- **Major strengths**

Our division has been recognized for a long time as being one that provides outstanding clinical teaching, mentoring skills as well as fulfills the academic mandate of being involved in both basic and clinical research.

**Academic facilities**
There is a well-equipped PICU, which admits our diabetic patients with DKA for intensive intravenous insulin management using our protocol. Neonatal ICU patients are seen at the MCH (9C) or in the two other MUHC Level II nurseries (RVH and JGH). Patients are usually seen first in the ER by our trainees, where investigation and treatment are initiated under staff supervision. Similarly, ICU’s and/or patients with other acute metabolic disorders (e.g. hypoglycaemia, adrenal crises, D.I., etc.) are seen first by the residents and then managed under our staff supervision. We prefer to admit non-diabetic patients to the ward teams so that the paediatric residents can participate in the care of these cases, and our residents can learn to function as consultants.

Interdisciplinary Communication

1. **Neuroendocrinology:** There is an active Dept. of Neurosurgery with 3 GFT staff. They see 359 new and 866 follow-up patients annually. We look after all pre-operative orders, include fluid balance, for patients undergoing hypothalamic-pituitary procedures. We also evaluate and follow-up those receiving cranial irradiation via Radiation Oncology.
2. **Imaging Dept.:** This is a large facility, including a new MRI. They perform over 73,200 procedures annually, including 3400 CT’s and 1600 MRI’s. We have monthly Neuroradiology - Endocrinology Rounds to review CT and MR studies. Examples of cases reviewed are congenital hypopituitarism and CNS tumours.
3. **Oncology:** Given the improving long term prognosis for children post therapies and the potential for endocrine disorders arising from chemo and/or radiotherapies, we follow a substantial proportion of these children.
4. **Nephrology:** We interact on numerous cases related to hypertension, Nephrogenic D.I., hypophosphatemic rickets, etc. We have part of our J. Club/Research Seminar series conjointly with them due to several collaborative research studies. Dr. Goodyer’s RASS study.
5. **Biochemical Genetics:** We interact on complex metabolic disorders, including proteinopathies and organic acidurias, including Glycogen Storage Disease patients, which we manage. Drs. Barnes and Mitchell are appointed to both Services and facilitate these interactions.
6. **Réseau Génetique:** We are responsible for the McGill component of the neonatal screening program for congenital hypothyroidism. Trainees are able to experience first-hand the operation and cost-benefit of this program.
7. **Intersex Management Team:** This team was structured in November 1991 to deal with the acute and chronic management of sexual differentiation disorders and neonatal sex assignment. Members consist of an endocrinologist
8. **Iatrogenic Cushings:** Many services (e.g. GI, Asthma Clinic, Neurosurgery, Dermatology) use pharmacologic glucocorticoids. This provides the opportunity for our trainees to see the adverse effects of steroids on linear growth and adrenal suppression. They are able to implement our protocol of tapering and discontinuation, with assessment of restoration of adrenal function.
9. **Nutrition Services:** Trainees interact regularly with the dieticians in care of our diabetic patients, being involved in the teaching of patients and their families. They also assist in the care of our patients with GSD, hypoglycaemia, ketogenic diets, under-nutrition and some high-risk Obesity patients. We do limited intervention for the other children with obesity using Canada Food Guide recommendations. We must return the patients to their own physicians,
local clinics (CLSC's, which may not offer paediatric support), and nutrition clinics or services such as Weight-Watchers.

10. **Psychosocial**: There is a full-time social worker assigned to our Service, R. D'Orazio, who particularly supports the diabetics. She attends the Diabetes Clinic, post-clinic psychosocial rounds and facilitates care for our Endocrine patients too. A psychiatrist, Dr. K. Minde, provides acute intervention when required. Dr. M. Sufrategui is available to provide psychological care of our diabetic patients. We meet with her monthly. Thus the trainees are regularly exposed to these significant aspects of chronic disease.

11. **Quality Assurance**: Dr. Barnes supervises this hospital-wide program. We regularly receive his input during Service rounds.

**Clinical Laboratory Facilities**

Clinical Endocrinology Laboratory: This laboratory is now under the auspices of Biochemistry. Dr. Celia Rodd has been the Medical Director for over 5 years. She serves on the MCH Laboratory Services Director's Committee and on the MUHC Laboratory Consolidation Committee. The interface between the Endocrine lab and Biochemistry is open and productive.

The above organization provides the trainees with opportunities for electives, but also provides ongoing input to important aspects of Laboratory Medicine, including cost-containment, and proper use of diagnostic laboratory facilities. Finally, this ensures that all important laboratory results are provided directly to the respective trainee and staff, for discussion at Service Rounds.

Pathology: Although we have a small and growing Pathology Division, we have been able to arrange several Endocrinology - Pathology Rounds every few years. The residents attend the weekly Tumor Board Rounds, if the cases are Endocrine in nature. The exposure is limited but steps have been taken to improve this, such as CD's and other teaching material in Pathology have been purchased to supplement the training.

Nuclear Medicine: Drs. Raymond Lambert and Turpin provide excellent service, even though they are based at Hôpital Ste-Justine. We have no difficulty with the scheduling and interpretation of neonatal thyroid scans, examinations for solitary thyroid nodules (isotope scans, ultrasound). The laboratory has recently been upgraded allowing us to perform 1131 scans. Additional Nuclear Medicine experience has been arranged with the JGH and was felt to be worthwhile.

Research Institute: There are two separate endocrine and metabolic research laboratories within the structure of the MCH Research Institute. These are:

a) Endocrine Research, Room R-415, MCH Research Institute, Place Toulon, C. Goodyer, Ph.D., Aimée Ryan, Ph.D.

b) Molecular Endocrinology, Room R-414, MCH Research Institute, Place Toulon, C. Polychronakos, MD

**Summary of Adequacy of Resources**
We are indeed fortunate to have the largest faculty for Paediatric Endocrinology & Metabolism in Canada. This luxury permits us to offer the expansive and controlled teaching program that we have in place. Each teaching staff/faculty member is expected to perform approximately 1/4 clinical service duties. This provides ample time for each of us to carry significant independent research careers, and to meet the teaching and patient care requirements of the Service. When providing service and teaching, the staff is expected to place his other activities into a secondary position for the relatively brief time required. The number of staff also guarantees that we can continue to function despite our overall commitments to CME activities, writing of grants and manuscripts, and other academic endeavours.

**Basic Science Laboratory of Dr Polychronakos:**

My laboratory at the Research Institute of the McGill University Health Center (Montreal Children’s Hospital site), occupies 2,000 square feet of space and has all the necessary equipment for molecular genetics, including equipment bought with a 2005 CFI grant to the Montreal Diabetes Research Center: A state of the art Janus robotic system, a fluorescence polarization detector for genotyping and a FACSaria cell sorter were awarded specifically to me within this $14M grant. In addition, the Institute has all required shared facilities including tissue culture (three incubators and two hoods exclusive to my lab, including one of each dedicated to ES cell work).

Through the GriD and diabetes genetics projects, I am also in close contact with the McGill/Genome Quebec Innovation Center (MGQIC). Ghislain Rocheleau, one of my current post-docs, is physically located full-time at the MGQIC and three members of the technical personnel there are my former research assistants, trained by me.

**Clinical:**

I am the director of endocrinology at the Montreal Children’s Hospital and have established a long-standing program for obtaining blood for research, both for DNA for functional studies on fresh blood cells. Total population almost 500 children (age over 18 years) with diabetes, almost all type 1. Research coordinator team has had a stellar record in past large-scale studies, such as the natural history nephropathy study, DPT1 and we are a major affiliate of Trial Net.

**Computer:**

Each senior member of my laboratory has access to a terminal connected to the hospital network. For large-scale data management, we have access to the Nankuq system at the McGill /Genome Quebec Innovation Centre (used routinely for our Genotyping) and for computationally demanding applications we can access the CLUMEQ supercomputing facility (used in Sladek et al. Nature 2007)

**Major Equipment:**

The Solexa system is being set up at the Center for Applied Genomics, Children’s Hospital of Philadelphia, which will do the resequencing on a collaborative basis, including all computational work.

Genotyping will be performed at MGQIC on the Sequenom iPlex system used in our previous publications.
Cell sorting for the expression studies will be performed on a FACSaria obtained by funds awarded to the PI by the CFE, specifically for use in diabetes research.

- **Library access, materials relevant to fellowship training**
  - McGill University: world-class with broad range of electronic journal subscription, Uptodate.com.
  - MCH Paediatric Library: well stocked, with on-line searching capability
  - Endocrine Sub-library: contains relevant textbooks and periodicals in two locations on E-315 (Clinical) and C-1228 (Research) and on-line searching capability
  - Staff offices - wide range of textbooks and articles.

- **Multimedial learning materials available- quote hospital details please**
  There are three computers with hardwire connections to allow for on-line searches, for downloading of articles and Internet and email in the two trainee offices. As well, all ward computers and support staff computers can be used for these activities, if needed because the computers are networked and allow multiusers.

- **Availability of a skills lab, if applicable- not applicable**

**Fellow Duties and Responsibilities**

- Call responsibilities to cover service- None
- Include whether the fellow is he senior supervisor of residents- No
- Outline whether threw are fixed rotations at various institutions- No
- Outpatient clinic responsibilities need to be outlined-

Generally the trainees are interested in attending either a general endocrinology clinic on Monday afternoons (1300-1700). 2 physicians and usually one endocrine resident staff this with perhaps a medical student and 1 or 2 residents. There are over 25 patients seen by the house staff. If the Fellow wishes to attend this clinic, then patients, who need to be seen more urgently and have been triaged to attend an ‘office’ visit by only the staff, could be seen by the Fellow. The staff, who would have evaluated the patient by themselves, can attend the clinic to review the case. If this staff is already booked in the clinic, then they will arrange their time to attend the clinic earlier than usual to review the Fellow's case/s. We have experience with this and have found that the house staff attending the usually scheduled clinic is given the usual amount of attention, while allowing the Fellow to see patients.

If the clinic has very few house staff assigned to it, as deemed by the Program Director, then the Fellow can attend and work in parallel with the usual house staff.
Weekly schedule

Monday afternoon- General endocrine clinic 1300- 1700 (if interested)*
Tuesday morning Diabetes clinic  0800- 1200 (if interested)*
Wednesday afternoon  1330- 1630 Diabetes/Endocrinology rounds, journal club or research presentation in the academic year
Thursday morning (twice per month) Lipid clinic 0900-1200*
Thursday afternoon 1330-1530 Endocrine resident teaching (if interested)
Friday afternoon- house staff teaching (Fellow may be the facilitator, if interested)

* the Fellow will select one of these clinics per week

☐

☐ Outline role of the fellow towards residents on service- None
☐ Teaching responsibilities towards residents- see above

☐ Outline participation in academician activities involving the residents: seminars, outcome assessment (morbidity and mortality rounds etc)

☐ Describe any support staff available to the fellow: program coordinator, nurse, clinician, secretarial
Our administrative secretary assists in coordinating all rotations, the application and acceptance process. If the Fellow participates in clinics, then he/she has access to our secretaries, who are in charge of the clinics.

☐ Proposed meetings to be attended by the fellows

☐ Additional pedagogic activities
All trainees are encouraged to attend at least one conference per year; this is often the Endocrine Society, American Diabetes Association or the Canadian Diabetes meeting/ Endocrinology meeting. Our division has adequate funding to assist with registration costs and some travel costs for endocrine residents and Fellows.
The Fellows are also able to be granted additional funds from the MCH research institute, if their abstracts have been accepted for presentation.

☐ Research productivity and publications expected by the Fellow

Most Fellows would be expected to present, prepare and present a abstract/manuscript that reflects their academic activities during the Fellowship. Some trainees may be capable of additional manuscripts. If she/he are enrolled in a graduate program, then their thesis would be
expected to be completed during the Fellowship or shortly thereafter, depending on the course or research load in that particular period.

Curriculum

- **Intended case load- none**
- **Intended percentage of varieties of cases- n/a**
- **Regular reading materials provided-**
- **Conference weekly schedules-**
  - Conferences/ Service Rounds:
    1. Pediatric Research Seminars, Room C-417, Mondays at 12:00h
    2. Endocrine Clinic Intake Conference, Room B-230, Mondays at 16:30h
    3. Endocrine Clinic Intake Conference, Room B-230, Tuesdays at 16:30h
    4. Diabetic Clinic Conference, Room C-1235, Wednesdays at 13:30h
    5. Endocrine/Metabolism Service Rounds, Room C-1235, Wednesdays at 14:30h
    6. Journal Club/Research Seminar Series, Room C-1235, Wednesdays at 15:30h
    7. Diabetes Clinic Rounds, Room A-311, Tuesdays at 11:30 monthly
    8. Diabetes Teaching for new diabetics, as required
    9. Endocrine Fellow Teaching Rounds, Room C-1235, Thursday 13:30h
    10. Short Cycle Teaching Rounds, E-315, Friday afternoons
    11. Pediatric Grand Rounds, D-182, Wednesdays at 8:00h
    12. Attendance at conjoint rounds and conferences:
      - MUHC Endocrine Combined Rounds, Thursdays at 8:00h

- **Role of fellow in attending, presenting, supervising, organization**
The Fellow is involved in presenting her/his research work, works to organize the year and weekly schedule and is involved in some supervisory activities but these are mostly related to her/his research.